HomeCompareAMRS vs NNN

AMRS vs NNN: Dividend Comparison 2026

AMRS yields 4000.00% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMRS wins by $7175340620755.84M in total portfolio value
10 years
AMRS
AMRS
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full AMRS calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — AMRS vs NNN

📍 AMRS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMRSNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMRS + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMRS pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMRS
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, AMRS beats the other by $5,813,155,604,218,158,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMRS + NNN for your $10,000?

AMRS: 50%NNN: 50%
100% NNN50/50100% AMRS
Portfolio after 10yr
$3587670310377.95M
Annual income
$3,419,503,296,598,919,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMRS right now

AMRS
Analyst Ratings
9
Buy
9
Hold
2
Sell
Consensus: Buy
Altman Z
-9.1
Piotroski
2/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMRS buys
0
NNN buys
0
No recent congressional trades found for AMRS or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMRSNNN
Forward yield4000.00%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$7175340620755.87M$25.5K
Annual income after 10y$6,839,006,593,197,835,000.00$2,622.67
Total dividends collected$7152397773804.84M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: AMRS vs NNN ($10,000, DRIP)

YearAMRS PortfolioAMRS Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$410,700$400,000.00$10,735$614.96+$400.0KAMRS
2$15,792,720$15,353,271.03$11,572$708.43+$15.78MAMRS
3$568,657,142$551,758,931.89$12,531$819.53+$568.64MAMRS
4$19,176,207,860$18,567,744,718.20$13,633$952.29+$19176.19MAMRS
5$605,696,028,890$585,177,486,479.73$14,909$1,111.84+$605696.01MAMRS
6$17,922,210,653,594$17,274,115,902,681.27$16,392$1,304.77+$17922210.64MAMRS
7$496,869,793,504,300$477,693,028,104,954.00$18,129$1,539.52+$496869793.49MAMRS
8$12,908,672,105,251,704$12,377,021,426,202,104.00$20,173$1,827.08+$12908672105.23MAMRS
9$314,330,866,876,668,540$300,518,587,724,049,200.00$22,597$2,181.81+$314330866876.65MAMRS
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$25,491$2,622.67+$7175340620755.84MAMRS

AMRS vs NNN: Complete Analysis 2026

AMRSStock

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Full AMRS Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this AMRS vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMRS vs SCHDAMRS vs JEPIAMRS vs OAMRS vs KOAMRS vs MAINAMRS vs ADCAMRS vs EPRTAMRS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.